National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 122
- 主要终点
- no response (yes/no) for children with autoimmune haemolytic anemias
研究概览
简要总结
This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.
详细描述
These autoimmune haematological diseases are rare diseases affecting the child, often very young, and serious and potentially life-threatening. International literature data are scarce, and include individual cases or small series.
They do not allow to determine an optimal therapeutic strategy in case of escape from the first-line treatments. Existing treatments (long-term corticosteroid therapy, immunoglobulins, splenectomy, immunosuppressants, chemotherapies, and more recently anti-CD20 antibodies) are inconsistently effective, and often associated with serious side effects.
The seriousness of these diseases, the therapeutic difficulties, and the absence of a targeted research project in France, led to the implementation of this study.
This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age strictly below 18 years of age at initial diagnosis
- •Affiliate child or beneficiary of a social security scheme
- •Child residing in metropolitan France
- •Diagnosis of autoimmune haemolytic anemias, Evans syndrome and / or chronic Immune thrombocytopenic purpura
- •Free, informed, written and signed consent
排除标准
- •Diagnosis of constitutional haemolytic anemia
- •Diagnosis of platelet constitutional disease
结局指标
主要结局
no response (yes/no) for children with autoimmune haemolytic anemias
时间窗: At the screening
Clinical Signs of Severe Anemia (Grade 3 or More) Or Hemoglobin \<7 g / dl
deceased patient (yes/no) for children with autoimmune haemolytic anemias
时间窗: At the screening
Death yes/no
partial remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
时间窗: At the screening
Clinical Signs of Hemorrhage (Grade 1 or 2) Or platelets between 30,000 and 100,000 / mm3
Complete sustainable remission (yes/no) for children with autoimmune haemolytic anemias
时间窗: At the screening
Absence of clinical signs of anemia (grade 0) And Hemoglobin \> 11 g / dl And reticulocytes \<120,000 / mm3 And haptoglobin\> 10 mg / dl And bilirubin \<10 mg / l or 17 μmol / l And no specific treatment for at least 12 months
partial remission (yes/no) for children with autoimmune haemolytic anemias
时间窗: At the screening
Clinical Signs of Anemia (Grade 1 or 2) Or Hemoglobin from 7 to 11 g / dl Or reticulocytes\> 120,000 / mm3 Regardless of the level of haptoglobin or bilirubin
complete remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
时间窗: At the screening
Absence of clinical signs of haemorrhage (grade 0) And platelets\> 100,000 / mm3 And specific treatment in progress or interrupted for less than 12 months
no response (yes/no) for children with chronic immunologic thrombocytopenic purpura
时间窗: At the screening
Clinical Signs of Severe Hemorrhage (Grade 3 or Greater) Or Platelets \<30,000 / mm3
deceased patient (yes/no) for children with chronic immunologic thrombocytopenic purpura
时间窗: At the screening
Death yes/no
complete remission (yes/no) for children with autoimmune haemolytic anemias
时间窗: At the screening
Absence of clinical signs of anemia (grade 0) And Hemoglobin\> 11 g / dl And reticulocytes \<120,000 / mm3 Regardless of the level of haptoglobin or bilirubin And specific treatment in progress or interrupted for less than 12 months
Complete sustainable remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
时间窗: At the screening
Absence of clinical signs of haemorrhage (grade 0) And platelets\> 100,000 / mm3 And no specific treatment for at least 12 months
次要结局
未报告次要终点